Full text of the congratulatory letter on the company's establishment anniversary from the General Director.
Dear Imexpharm members,
In 2023, we continue to count the steady and swift beats, marking many stories of individuals and organizations in this flow. For Imexpharm Pharmaceutical Joint Stock Company, this is the 46th year in its history of formation and development.
Through a journey of more than half a lifetime full of trials and challenges, with a spirit of unity never faltering and relentless efforts of the collective body of staff, workers of the Company, and certainly not without the support and companionship from valued partners and shareholders, Imexpharm has overcome all difficulties, surpassing its own records at every stage of the journey. Therefore, as Imexpharm enters this traditional 46th year, the members here once again have the opportunity to "review and renew", proud of the footsteps taken along with the steps in line with the common goal of the entire collective carrying the breath of the new era.
Looking back at 1977 when Imexpharm was established as a Level II Pharmaceutical Company, it laid a solid foundation for the success of the Imexpharm brand in both domestic and international markets today. Throughout its history, one of the most memorable events for Imexpharm was the factory fire in 1994, which forced the work to start over from scratch. With the economic and social situation still in the process of renewal, this was truly a major shock for a fledgling enterprise. However, thanks to the unity and dedication of the collective body of staff, workers, along with the assistance from business partners and valued partners, Imexpharm then surpassed the difficulties and continued to develop.
Since then, Imexpharm has taken breakthrough steps and achieved an important position in the pharmaceutical market. As witnesses to numerous ups and downs and events, we are proud of Imexpharm's ability to always be ready to experiment and explore new fields, surpassing almost unprecedented limits. Notable achievements include: achieving GMP - ASEAN standards as the first pharmaceutical enterprise in 1997, going public as the first pharmaceutical enterprise in 2001, listing on the stock market as the first pharmaceutical enterprise in 2006, implementing SAP-ERP solutions in system management in 2013. In 2016, Imexpharm had the honor of becoming the first pharmaceutical enterprise with 3 Betalactam antibiotic production lines meeting EU-GMP standards, certified by the Ministry of Health of Spain. In 2021, Imexpharm commenced commercial operation of the Health Food Plant at its headquarters in Cao Lanh with an investment of nearly VND 90 billion…
To achieve this important milestone, over the past 46 years, Imexpharm has seized every opportunity to invest in advanced technology and infrastructure. Pioneering in building manufacturing plants to international standards; focusing on training and developing human resources; quickly diversifying product portfolios; innovating technology to enhance competitive capacity in the market…, Imexpharm has realized commitments with investors, partners, employees, customers, and the community, leaving the iconic lotus symbol on the map of the Pharmaceutical industry at home and abroad. In today's flat world, Imexpharm is proud to be able to introduce itself in any language, with any culture, but also proud of the voice of an enterprise rising from the Dong Thap Muoi region in the difficult post-war period. That voice is a resounding echo, strongly resonating with over a thousand members of all sizes from many generations of Imexpharm people, constantly changing with the times, but still retaining a heartfelt desire to contribute.
In 2023, it continues to be an opportunity for Imexpharm to enhance its position in the international market. By taking another step in shaping the strategy towards 2030, restructuring the management system, officially putting the IMP4 plant into operation, promoting product exports abroad, and attracting attention from many countries around the world. Imexpharm's continuous development has played an important role in raising awareness of quality of life and healthcare. No longer just about treating illnesses with drugs, or manufacturing under conditions, or selling for revenue, Imexpharm focuses on building a healthy work environment, helping each member maintain the best physical and mental condition, helping each individual customer and enterprise understand the value of products from Imexpharm, helping each locality where Imexpharm is present benefit from the activities created by Imexpharm. This is truly a revolution in values and Imexpharm is proud to have seriously learned and improved over the past 05 years to have a strong team and a solid foundation as today.
2023 is also the beginning of a promising new term of the 2023 - 2027 Board of Directors with outstanding results in the first 06 months of the year with revenue growth of 37% and profit growth of 59% compared to the same period. In addition, the deep involvement of SK Group, a leading investor from South Korea, Imexpharm will have the opportunity to elevate its enterprise management to a new level. SK Group's participation in Imexpharm's corporate governance activities not only brings top-notch management knowledge and experience but also provides opportunities for Imexpharm's business expansion and scale-up.
With support from the SK Group, Imexpharm will have the opportunity to improve the quality of corporate management, enhance competitiveness in the market, and help expand Imexpharm's business scale. The application of advanced management methods and international standards will help Imexpharm improve operational processes, enhance adaptability, and increase the company's work efficiency.
Imexpharm has gone through a long journey to become a reputable and successful brand. With the dedication and passion of the staff, we have overcome all challenges, and the important milestones of 2023 will be the next turning point in our development journey. Imexpharm will continue to innovate strongly to bring the best quality products and services to customers and build a happy, sustainable working environment for each member. At the same time, with love and pride for the homeland, Imexpharm has and will continue to contribute to social and community activities. By committing to accompany organizations and individuals in improving health for people, Imexpharm also continues to search for and apply new solutions to improve the quality of human life. Furthermore, Imexpharm believes in the future generation and the measure of sustainable development, so it is committed to continue investing in the quality of special human resources, especially local human resources, to meet the increasingly high demands of work and affirm pride in the successor team.
For today and the decades to come, Imexpharm sincerely appreciates all the staff and workers of Imexpharm who have accompanied and devoted themselves to the company's development process. Everyone's continuous efforts and investments have played an important part in Imexpharm's success today. Imexpharm calls on all company members along with Imexpharm to explore new possibilities, new knowledge, new technologies, and together build a better future for everyone, including ourselves.
Imexpharm also wishes health and peace to everyone, because health and peace are the most valuable things we can expect in this modern life. Imexpharm hopes that everyone always has enough health to face challenges in both work and life. As the full emotions of the commemorative tradition of the 45th anniversary "accompanying the months and years of the country", on behalf of all members of the previous generations, thank you everyone who has walked with Imexpharm on this journey despite many challenges but full of sincerity. Thank you, life, for giving us the opportunity to be together to write history.
Cao Lanh City, July 24, 2023
General Director
TTNN, DS. Tran Thi Dao